MDSC-targeted liposomal all-trans retinoic acid suppresses mMdscs and improves immunotherapy in HBV infection

References

• Khanam A, Ayithan N, Tang L, et al. IL-21–deficient T follicular helper cells support B cell responses through IL-27 in patients with chronic hepatitis B. Front Immunol. 2021;11:599648. doi: 10.3389/fimmu.2020.599648
   PubMed Web of Science ®Google Scholar
• Zhang J, Lin S, Jiang D, et al. Chronic hepatitis B and non‐alcoholic fatty liver disease: conspirators or competitors? Liver Int. 2020;40(3):496–508. doi: 10.1111/liv.14369
   PubMed Web of Science ®Google Scholar
• Wong GH, Wong VS, Chan HY. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. J Viral Hepat. 2014;21(12):825–834. doi: 10.1111/jvh.12341
   PubMed Web of Science ®Google Scholar
• Fung J, Lai C-L, Seto W-K, et al. Nucleoside/Nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011;66(12):2715–25. doi: 10.1093/jac/dkr388
   PubMed Web of Science ®Google Scholar
• Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81(8):4215–25. doi: 10.1128/JVI.02844-06
   PubMed Web of Science ®Google Scholar
• Martinez MG, Villeret F, Testoni B, et al. Can we cure hepatitis B virus with novel direct‐acting antivirals? Liver Int. 2020;40(S1):27–34. doi: 10.1111/liv.14364
   PubMedGoogle Scholar
• Chapman TM, McGavin JK, Noble S. Tenofovir disoproxil fumarate. Drugs. 2003;63(15):1597–608. doi: 10.2165/00003495-200363150-00006
   PubMed Web of Science ®Google Scholar
• Dando TM, Plosker GL. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs. 2003;63(20):2215–34. doi: 10.2165/00003495-200363200-00007
   PubMed Web of Science ®Google Scholar
• Wang Y, Thongsawat S, Gane E, et al. Efficacy and safety of continuous 4‐year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20(4):e37–e46. doi: 10.1111/jvh.12025
   PubMed Web of Science ®Google Scholar
• Luo A, Jiang X, Ren H. Lamivudine therapy for chronic hepatitis B in children: a meta-analysis. Virol J. 2019;16(1):1–9. doi: 10.1186/s12985-019-1193-x
   PubMedGoogle Scholar
• Charlton MR, Alam A, Shukla A, et al. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020;55(9):811–823. doi: 10.1007/s00535-020-01698-4
   PubMed Web of Science ®Google Scholar
• Lee SW, Choi J, Kim SU, et al. Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol. 2021;27(3):402. doi: 10.3350/cmh.2021.0179
   PubMed Web of Science ®Google Scholar
• Roca Suarez AA, Testoni B, Zoulim F. HBV 2021: new therapeutic strategies against an old foe. Liver Int. 2021;41(S1):15–23. doi: 10.1111/liv.14851
   PubMedGoogle Scholar
• Downs LO, Smith DA, Lumley SF, et al. Electronic health informatics data to describe clearance dynamics of hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in chronic hepatitis B virus infection. MBio. 2019;10(3):e00699–19. doi: 10.1128/mBio.00699-19
   PubMed Web of Science ®Google Scholar
• Boni C, Janssen HL, Rossi M, et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology. 2019;157(1):227–41. e7. doi: 10.1053/j.gastro.2019.03.044
   PubMed Web of Science ®Google Scholar
• Lee HM, Banini BA. Updates on chronic HBV: current challenges and future goals. Curr Treat Options Gastroenterol. 2019;17(2):271–91. doi: 10.1007/s11938-019-00236-3
   PubMedGoogle Scholar
• Kong X, Sun R, Chen Y, et al. γδT cells drive myeloid-derived suppressor cell–mediated CD8+ T cell exhaustion in hepatitis B virus–induced immunotolerance. J Immunol. 2014;193(4):1645–53. doi: 10.4049/jimmunol.1303432
   PubMed Web of Science ®Google Scholar
• Yang F, Yu X, Zhou C, et al. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLOS Pathogens. 2019;15(4):e1007690. doi: 10.1371/journal.ppat.1007690
   PubMed Web of Science ®Google Scholar
• Meng-Er H, Yu-Chen Y, Shu-Rong C, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567–572. doi: 10.1182/blood.V72.2.567.567
   PubMed Web of Science ®Google Scholar
• Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20(49):7140–5. doi: 10.1038/sj.onc.1204763
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Fishman M, Sherman S, et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007;67(22):11021–8. doi: 10.1158/0008-5472.CAN-07-2593
   PubMed Web of Science ®Google Scholar
• Zheng A, Xie F, Shi S, et al. Sustained drug release from liposomes for the remodeling of systemic immune homeostasis and the tumor microenvironment. Front Immunol. 2022;13. doi: 10.3389/fimmu.2022.829391
   Web of Science ®Google Scholar
• Xu Y, Chen X, Zheng A, et al. All-trans retinoic acid injectant and application. Google Pat. 2021. https://patents.google.com/patent/US10952984B2/en
   Google Scholar
• Feng S, Cheng X, Zhang L, et al. Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. Proc Nat Acad Sci. 2018;115(40):10094–10099. doi: 10.1073/pnas.1800695115
   PubMed Web of Science ®Google Scholar
• F-Y M, Y-L Z, Y-P L, et al. CD45+ CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8+ T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer. Cell Death Dis. 2018;9(7):763. doi: 10.1038/s41419-018-0803-7
   PubMedGoogle Scholar
• Dar AA, Patil RS, Pradhan TN, et al. Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma. Cancer Immunol Immunother. 2020;69(6):1071–86. doi: 10.1007/s00262-020-02523-w
   PubMed Web of Science ®Google Scholar
• Solito S, Pinton L, De Sanctis F, et al. Methods to measure MDSC immune suppressive activity in vitro and in vivo. Curr Protoc Immunol. 2019;124(1):e61. doi: 10.1002/cpim.61
   PubMedGoogle Scholar
• Huang B, Pan P-Y, Li Q, et al. Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123–31. doi: 10.1158/0008-5472.CAN-05-1299
   PubMed Web of Science ®Google Scholar
• Bogue MA, Philip VM, Walton DO, et al. Mouse phenome database: a data repository and analysis suite for curated primary mouse phenotype data. Nucleic Acids Res. 2020;48(D1):D716–D23. doi: 10.1093/nar/gkz1032
   PubMed Web of Science ®Google Scholar
• Vanhaver C, van der Bruggen P, Bruger AM. MDSC in mice and men: mechanisms of immunosuppression in cancer. J Clin Med. 2021;10(13):2872. doi: 10.3390/jcm10132872
   PubMed Web of Science ®Google Scholar
• Youn J-I, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–802. doi: 10.4049/jimmunol.181.8.5791
   PubMed Web of Science ®Google Scholar
• Chen Q, Yuan S, Sun H, et al. CD3+ CD20+ T cells and their roles in human diseases. Hum Immunol. 2019;80(3):191–4. doi: 10.1016/j.humimm.2019.01.001
   PubMed Web of Science ®Google Scholar
• Lombardo L, Capaldi A, Poccardi G, et al. Peripheral blood CD3 and CD4 T-lymphocyte reduction correlates with severity of liver cirrhosis. Int J Clin Lab Res. 1995;25(3):153–156. doi: 10.1007/BF02592558
   PubMedGoogle Scholar
• Shin E-C, Sung PS, Park S-H. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16(8):509–23. doi: 10.1038/nri.2016.69
   PubMed Web of Science ®Google Scholar
• Alter HJ, Chisari FV. Is elimination of hepatitis B and C a pipe dream or reality? Gastroenterology. 2019;156(2):294–6. doi: 10.1053/j.gastro.2018.12.015
   PubMed Web of Science ®Google Scholar
• Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545–58. doi: 10.1016/S2468-1253(19)30119-0
   PubMed Web of Science ®Google Scholar
• Shi B, Wu Y, Wang C, et al. Evaluation of antiviral-passive-active immunization (“sandwich”) therapeutic strategy for functional cure of chronic hepatitis B in mice. EBioMedicine. 2019;49:247–57. doi: 10.1016/j.ebiom.2019.10.043
   PubMed Web of Science ®Google Scholar
• Zhu H, Gu Y, Xue Y, et al. CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion. Oncotarget. 2017;8(70):114554. doi: 10.18632/oncotarget.23020
   PubMedGoogle Scholar
• Zheng C, Yan H, Zeng J, et al. Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. Infect Drug Resist. 2019;12:845–54. doi: 10.2147/IDR.S195144
   Web of Science ®Google Scholar
• Fung S, Choi HS, Gehring A, et al. Getting to HBV cure: the promising paths forward. Hepatology. 2022;76(1):233–250. doi: 10.1002/hep.32314
   PubMed Web of Science ®Google Scholar
• Raskov H, Orhan A, Gaggar S, et al. Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy. Oncogenesis. 2022;11(1):22. doi: 10.1038/s41389-022-00398-3
   PubMed Web of Science ®Google Scholar
• Alicea-Torres K, Sanseviero E, Gui J, et al. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat Commun. 2021;12(1):1717. doi: 10.1038/s41467-021-22033-2
   PubMed Web of Science ®Google Scholar
• Yang D, Liu L, Zhu D, et al. A mouse model for HBV immunotolerance and immunotherapy. Cell Mol Immunol. 2014;11(1):71–8. doi: 10.1038/cmi.2013.43
   PubMed Web of Science ®Google Scholar
• Huang L-R, Wu H-L, Chen P-J, et al. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Nat Acad Sci. 2006;103(47):17862–17867. doi: 10.1073/pnas.0608578103
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen S-H, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7(1):12150. doi: 10.1038/ncomms12150
   PubMed Web of Science ®Google Scholar
• Cassetta L, Baekkevold ES, Brandau S, et al. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother. 2019;68(4):687–97. doi: 10.1007/s00262-019-02302-2
   PubMed Web of Science ®Google Scholar
• Wang X, Zhu J, Zhang Y, et al. The doses of plasmid backbone plays a major role in determining the HBV clearance in hydrodynamic injection mouse model. Virol J. 2018;15(1):1–8. doi: 10.1186/s12985-018-1002-y
   PubMedGoogle Scholar
• Li X, Liu G, Chen M, et al. A novel hydrodynamic injection mouse model of HBV genotype C for the study of HBV biology and the anti-viral activity of lamivudine. Hepatitis Mon. 2016;16(2). doi: 10.5812/hepatmon.34420
   Web of Science ®Google Scholar
• Li L, Li S, Zhou Y, et al. The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model. Virol J. 2017;14(1):1–11. doi: 10.1186/s12985-017-0874-6
   PubMedGoogle Scholar
• Allweiss L, Dandri M. Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J Hepatol. 2016;64(1):S17–S31. doi: 10.1016/j.jhep.2016.02.012
   PubMedGoogle Scholar
• Yang PL, Althage A, Chung J, et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Nat Acad Sci. 2002;99(21):13825–13830. doi: 10.1073/pnas.202398599
   PubMed Web of Science ®Google Scholar
• Liu C, Yu S, Kappes J, et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood. 2007;109(10):4336–42. doi: 10.1182/blood-2006-09-046201
   PubMed Web of Science ®Google Scholar
• Knaul JK, Jörg S, Oberbeck-Mueller D, et al. Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. Am J Respir Crit Care Med. 2014;190(9):1053–66. doi: 10.1164/rccm.201405-0828OC
   PubMed Web of Science ®Google Scholar
• Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol. 2009;182(1):240–9. doi: 10.4049/jimmunol.182.1.240
   PubMed Web of Science ®Google Scholar
• Baumann T, Dunkel A, Schmid C, et al. Regulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal. Nat Immunol. 2020;21(5):555–566. doi: 10.1038/s41590-020-0666-9
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Ochoa AC, Al-Khami AA. Arginine metabolism in myeloid cells shapes innate and adaptive immunity. Front Immunol. 2017;8:93. doi: 10.3389/fimmu.2017.00093
   PubMed Web of Science ®Google Scholar
• Sanchez-Pino MD, Dean MJ, Ochoa AC. Myeloid-derived suppressor cells (MDSC): when good intentions go awry. Cell Immunol. 2021;362:104302. doi: 10.1016/j.cellimm.2021.104302
   PubMed Web of Science ®Google Scholar
• Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology. 2009 May;49(S5):S166–73. doi: 10.1002/hep.22899
   PubMedGoogle Scholar
• Wu S, Yi W, Gao Y, et al. Immune mechanisms underlying hepatitis b surface antigen seroclearance in chronic hepatitis b patients with viral coinfection. Front Immunol. 2022;13:893512. doi: 10.3389/fimmu.2022.893512
   PubMed Web of Science ®Google Scholar
• Fang Z, Li J, Yu X, et al. Polarization of monocytic myeloid-derived suppressor cells by hepatitis B surface antigen is mediated via ERK/IL-6/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection. J Immunol. 2015;195(10):4873–83. doi: 10.4049/jimmunol.1501362
   PubMed Web of Science ®Google Scholar
• Pal S, Nandi M, Dey D, et al. Myeloid‐derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther. 2019;49(10):1346–59. doi: 10.1111/apt.15226
   PubMed Web of Science ®Google Scholar
• Huang A, Zhang B, Yan W, et al. Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1–induced IL-10. J Immunol. 2014;193(11):5461–9. doi: 10.4049/jimmunol.1400849
   PubMed Web of Science ®Google Scholar
• Menon AP, Moreno B, Meraviglia-Crivelli D, et al. Modulating T cell responses by targeting CD3. Cancers (Basel). 2023;15(4):1189. doi: 10.3390/cancers15041189
   PubMed Web of Science ®Google Scholar
• Dong D, Zheng L, Lin J, et al. Structural basis of assembly of the human T cell receptor–CD3 complex. Nature. 2019;573(7775):546–52. doi: 10.1038/s41586-019-1537-0
   PubMed Web of Science ®Google Scholar
• Liu X, He L, Han J, et al. Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer. Plos One. 2017;12(2):e0170605. doi: 10.1371/journal.pone.0170605
   PubMed Web of Science ®Google Scholar
• Ruan P, Yang C, Su J, et al. Histopathological changes in the liver of tree shrew (tupaia belangeri chinensis) persistently infected with hepatitis B virus. Virol J. 2013;10(1):1–11. doi: 10.1186/1743-422X-10-333
   PubMedGoogle Scholar
• Chu C-M, Yeh C-T, Chien R-N, et al. The degrees of hepatocyte nuclear but not cytoplasmic expression of hepatitis B core antigen reflect the level of viral replication in chronic hepatitis B virus infection. J Clin Microbiol. 1997;35(1):102–105. doi: 10.1128/jcm.35.1.102-105.1997
   PubMed Web of Science ®Google Scholar
• Chu C-M, Shyu W-C, Liaw Y-F. Immunopathology on hepatocyte expression of HBV surface, core, and x antigens in chronic hepatitis B: clinical and virological correlation. Dig Dis Sci. 2010;55(2):446–51. doi: 10.1007/s10620-009-0895-0
   PubMed Web of Science ®Google Scholar